Mr. Martin Felsenthal serves as Partner at Health Velocity Capital. He has worked exclusively with innovative, disruptive, and rapidly growing healthcare software and services companies for more than 20 years. He was previously a partner at two leading venture and growth capital firms focused on this sector -- Salix Ventures and HLM Venture Partners - and also worked with Madison Dearborn Partners earlier in his career. He has led investments in and/or served on the Boards of Directors of companies such as TelaDoc (NYSE: TDOC); Change Healthcare (acquired by Emdeon); Aperio (acquired by Leica Biosystems); Titan Health (acquired by United Surgical Partners); US Renal Care (acquired by Leonard Green); Payerpath (acquired by Misys/Allscripts); Vantage Oncology (acquired by McKesson); NovoLogix (acquired by CVS Health); VeriCare (acquired by MedOptions); OnShift; and ClearData Networks. Marty received his AB from Princeton University and his MBA from the Stanford University Graduate School of Business.